INSP Board Authorizes $200M Buyback; Press Release Filed as Exhibit 99.1

Rhea-AI Filing Summary

Inspire Medical Systems disclosed that its Board has authorized the repurchase of up to $200.0 million of the company’s outstanding common stock. The filing indicates the board approved a buyback authorization but does not include details on timing, methods, or the pace of repurchases.

The filing also furnishes the company press release as Exhibit 99.1 and includes Inline XBRL cover page tags. No financial results, program specifics, or additional transaction terms are provided within this report.

Positive

• Board authorization of up to $200.0 million for share repurchases, providing capacity for future buybacks

Negative

• None.

Insights

Financial Analyst

TL;DR: Board authorized a $200M share repurchase; specifics on timing and execution are not included in the filing.

The authorization to repurchase up to $200.0 million of common stock is a clear capital-allocation decision that can affect share count if executed. The filing supplies the press release as Exhibit 99.1 but omits operational details such as the repurchase time frame, repurchase methods, or any limit per period. Without those execution details or related financial context in this report, market impact will depend on subsequent disclosures or activity.

Corporate Governance Expert

TL;DR: Board-level approval for a $200M buyback was disclosed; the filing provides the announcement but not program mechanics.

This Form 8-K communicates a board authorization for a significant buyback amount and attaches the related press release as an exhibit. The filing does not describe authorization terms, repurchase authority limits, or any changes to executive compensation or governance tied to the program. Governance observers should note the action is documented, but further filings or the press release itself are needed for full governance implications.

0001609550False00016095502025-08-112025-08-11

SECURITIES AND EXCHANGE

Washington, D.C. 20549

_________________________

FORM 8-K

_________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): August 11, 2025

_________________________

INSPIRE MEDICAL SYSTEMS, INC.

(Exact name of registrant as specified in its charter)

_________________________

Delaware

001-38468

26-1377674

(State or other jurisdiction of incorporation)

(Commission File Number)

(I.R.S. Employer Identification No.)

5500 Wayzata Blvd., Suite 1600

Golden Valley, Minnesota 55416

(Address of principal executive offices) (Zip Code)

(844) 672-4357

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.001 par value per share

INSP

New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company     ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition

period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

On August 11, 2025, Inspire Medical Systems, Inc. (the “Company”) issued a press release announcing that its Board of Directors has authorized the repurchase of up to $200.0 million of the Company’s outstanding shares of common stock. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01.    Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.						Description
99.1						Inspire Medical Systems, Inc. press release dated August 11, 2025.
104						Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

						INSPIRE MEDICAL SYSTEMS, INC.
Date:			August 11, 2025			By:			/s/ Bryan K. Phillips
									Bryan K. Phillips
									Sr. Vice President, General Counsel

3

FAQ

What did Inspire Medical Systems (INSP) announce in this 8-K?

The company announced that its Board authorized the repurchase of up to $200.0 million of its outstanding common stock.

Where can I find the full text of the announcement for INSP?

The filing states the press release containing the announcement is furnished as Exhibit 99.1 to this Current Report.

Does the 8-K specify the timing or method for the repurchases?

No. The 8-K notes the authorization amount but does not provide timing, methods, minimum or maximum per period, or other execution details.

Does this filing include financial statements or program details for the buyback?

The filing lists exhibits (including Inline XBRL cover page tags) but does not include financial statements or detailed buyback program terms in the body of the report.

Who signed the Form 8-K for Inspire Medical Systems?

The report is signed by Bryan K. Phillips, Senior Vice President, General Counsel.